Formulary
Dalbavancin: Indications, Dosing, Side Effects and Interactions
Dalbavancin is a glycopeptide antibacterial; it has bactericidal activity against Gram-positive bacteria including various staphylococci.
MedNext Academy | 3 min read
Dalbavancin: Indications, Dosing, Side Effects and Interactions
Dalbavancin is a glycopeptide antibacterial; it has bactericidal activity against Gram-positive bacteria including various staphylococci.
Drug action
Dalbavancin is a glycopeptide antibacterial; it has bactericidal activity against Gram-positive bacteria including various staphylococci. However, there are reports of Staphylococcus aureus with reduced susceptibility to glycopeptides and increasing reports of glycopeptide-resistant enterococci.
Indications and dose
**Acute bacterial skin and skin structure infections**
- **Adult** (By Intravenous Infusion): 1500 mg for 1 dose, alternatively 1000 mg, then 500 mg after 1 week.
Side effects
Common or very common With intravenous use Diarrhoea; headache; nausea Uncommon With intravenous use Anaemia; appetite decreased; Clostridioides difficile colitis; constipation; cough; dizziness; eosinophilia; flushing; gastrointestinal discomfort; increased risk of infection; infusion related reaction; insomnia; leucopenia; neutropenia; skin reactions; taste altered; thrombocytosis; vomiting; vulvovaginal pruritus Rare or very rare With intravenous use Bronchospasm Frequency not known With intravenous use Ototoxicity
Pregnancy
Manufacturer advises avoid unless essential-toxicity in animal studies.
Breast feeding
Manufacturer advises avoid-present in milk in animal studies.
Hepatic impairment
Manufacturer advises caution in moderate to severe impairment (no information available).
Renal impairment
Dose adjustments Manufacturer advises reduce dose to 1000 mg as a single infusion or reduce dose to 750 mg followed one week later by 375 mg if creatinine clearance less than 30 mL/minute. See Prescribing in renal impairment .
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Dalbavancin in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

